Published in final edited form as:

Analyst. 2015 November 7; 140(21): 7062–7081. doi:10.1039/c5an00780a.

Biomarker detection for disease diagnosis using cost-effective microfluidic platforms

Sharma T. Sanjay^a, Guanglei Fu^a, Maowei Dou^a, Feng Xu^{b,c}, Rutao Liu^d, Hao Qi^e, and XiuJun Li^{a,f,g}

^aDepartment of Chemistry, University of Texas at El Paso, 500 West University Ave, El Paso, Texas, 79968, USA

^bBioinspired Engineering and Biomechanics Center (BEBC), Xi'an Jiaotong University, Xi'an 710049, P.R. China

^cMOE Key Laboratory of Biomedical Information Engineering, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, P.R. China

^dSchool of Environmental Science and Engineering, China -America CRC for Environment & Health, Shandong Province, Shandong University, 27# Shanda South Road, Jinan 250100, P.R. China

^eSchool of Chemical Engineering and Technology, Tianjin University, Tianjin, 300072, PR China

^fBiomedical Engineering, University of Texas at El Paso, 500 West University Ave, El Paso, Texas, 79968, USA

^gBorder Biomedical Research Center, University of Texas at El Paso, 500 West University Ave, El Paso, Texas, 79968, USA

Abstract

Early and timely detection of disease biomarkers can prevent the spread of infectious diseases, and drastically decrease the death rate of people suffering from different diseases such as cancer and infectious diseases. Because conventional diagnostic methods have limited application in low-resource settings due to the use of bulky and expensive instrumentation, simple and low-cost point-of-care diagnostic devices for timely and early biomarker diagnosis, is the need of the hour, especially in rural areas and developing nations. The microfluidics technology possesses remarkable features for simple, low-cost, and rapid disease diagnosis. There have been significant advances in the development of microfluidic platforms for diseases biomarker detection. This article reviews recent advances in biomarker detection using cost-effective microfluidic devices for disease diagnosis, with the emphasis on infectious disease and cancer diagnosis in low-resource settings. This review first introduces different microfluidic platforms (e.g. polymer and paper-based microfluidics) used for disease diagnosis, with a brief description of their common fabrication techniques. Then, it highlights various detection strategies for disease biomarker

[†]These might include comments relevant to but not central to the matter under discussion, limited experimental and spectral data, and crystallographic data.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here].
See DOI: 10.1039/b000000x/

detection using microfluidic platforms, including colorimetric, fluorescence, chemiluminescence, electrochemiluminescence (ECL), and electrochemical detection. Finally, it discusses the current limitations of microfluidics devices for disease biomarker detection and the future perspectives.

Graphical Abstract

This article reviews recent advances of biomarker detection for disease diagnosis using various cost-effective microfluidic platforms.

Keywords

Biomarker detection; Point-of-care diagnosis; Microfluidic lab-on-a-chip; Polymer and paper-based microfluidic devices; Disease diagnosis; Cancer; Infectious diseases

1. Introduction

As a disease attacks a person, physiological signals that represent the biological state of the person change in response to the status of the disease. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, pharmacologic responses to therapeutic intervention or any measurable diagnostic indicator for assessing the risk or presence of a disease.¹ It can include mRNA expression profiles, circulating DNA and tumor cells, proteins, proteomic pattern, lipids, metabolites, imaging methods or electrical signals.²⁻⁵ These signals/biomarkers may be obtained from sources such as urine, blood and tissues. Disease biomarker detection that is desired to be accurate, relatively noninvasive and easy to perform, even in point-of-care (POC) settings, can improve the screening, diagnosis, prognosis and recovery on treatment of various diseases.

Acute infectious diseases caused by pathogenic organisms such as bacteria, viruses, fungi and parasites have been a major cause of global death and high disability rates throughout the human history.^{6, 7} In developing nations, even curable infectious diseases pose a great threat to patients due to lack of affordable diagnosis.⁸ According to a global report on infectious disease of poverty (2012) by World Health Organization (WHO), each year infectious diseases kill 3.5 million people, mostly the poor and young children who live in

low and middle-income countries.⁹ Over 95% of deaths by infectious disease are due to the lack of proper diagnosis and treatment, and difficulty in accessing adequate healthcare infrastructures.⁸ Along with infectious diseases, cancer, the uncontrolled growth of abnormal cells which can spread and invade other parts of the body through the blood and lymph system, also figures among a leading cause of death worldwide with 8.2 million deaths in 2012, according to WHO.¹⁰ Annual cancer cases are expected to rise from 14 million in 2014 to 22 million within next 2 decades. Similar to infectious diseases, high incidence of cancer occurs in developing nations. According to WHO, 8 million (57%) of new cancer cases, 5.3 million (65%) of cancer deaths and 15.6 million (48%) of 5-year prevalence cancer cases, occurred in less developed regions.¹¹

Infectious diseases and cancer along with other diseases are mostly diagnosed by biomarker detection in laboratories using conventional tests such as enzyme linked immunosorbent assay (ELISA), immunofluorescence, western blotting, immunodiffusion, polymerase chain reaction (PCR), flow cytometry and a wide range of other techniques.^{12–14} However, most of these assays are complex, take hours to complete, consume large volumes of samples and reagents, and require bulky and expensive instruments limiting their applications in rural areas and developing nations. Therefore, simple, low-cost, portable diagnostic devices and methods, especially point-of-care (POC) diagnostic devices that offer great potential to detect and monitor diseases, even at resource-limited settings are in great need. Development of POC devices for simple, timely and early disease diagnosis can prevent the spread of infectious diseases, and decrease cancer fatality, as many cancer patients (including breast, colorectal, oral and cervical) have high chance to be cured if detected early and treated adequately. WHO has developed a list of general characteristics that make a diagnostic test appropriate for resource-limited sites, abbreviated as ASSURED, and includes, Affordable by those at risk, Sensitive, Specific, User-friendly, Rapid treatment and robust use, Equipment-free and finally Delivered to those who need it.¹⁵

Microfluidics technology possesses remarkable features for simple, low-cost, and rapid disease diagnosis, such as low volumes of reagent consumption, fast analysis, high portability along with integrated processing and analysis of complex biological fluids with high sensitivity for health care application.^{16–22} An enormous number of microfluidic devices have been developed for biomedical applications.^{23–29} These devices enable on-chip POC diagnosis and real-time monitoring of diseases from a small volume of body fluids. These microfluidic devices may act as a bridge to improve the global health care system with high efficiency and sensitivity, especially for remote areas with low-resource settings, such as the underdeveloped and developing countries, in home health care setting, and in emergency situations. Because of all these significant features, numerous microfluidic devices have been developed for the biomarker detection in disease diagnosis, which includes different types of cancer^{30–32} from colorectal carcinoma^{33, 34} and hepatocellular carcinoma³² to ovarian cancer^{33, 35} and prostate cancer,^{36, 37} different types of infectious diseases from food-borne pathogen³⁸ and Hepatitis B³⁹ to meningitis^{40, 41} and dengue virus,⁴² and other diseases from cardiovascular disease^{43, 44} to Alzheimer's diseases.⁴⁵ These microfluidic platforms includes glass,^{21, 46, 47} polydimethylsiloxane (PDMS),^{45, 48, 49} poly(methyl methacrylate) (PMMA),^{36, 50, 51} poly(cyclic olefin),^{52, 53} paper-based,^{23, 54–59} and hybrid devices.^{36, 60, 61}

This article reviews recent advances of biomarker detection for disease diagnosis using microfluidic techniques. It first introduces different microfluidic POC platforms used for disease biomarker detection with a brief introduction of their common fabrication techniques. Because of their ease of fabrication, cost-effective characteristics, and broad applications in disease diagnosis, it mainly focuses on cost-effective microfluidic platforms such as polymer (e.g. PDMS and PMMA) and paper-based microfluidic platforms. Next, it highlights various detection strategies for disease biomarker detection using microfluidic devices, including colorimetric, fluorescence, chemiluminescence, electrochemiluminescence (ECL), and electrochemical detection. Lastly, we briefly discuss the future trends of this field. Although microfluidic platforms have great potential for the diagnosis of a broad range of diseases, this article emphasizes the applications of microfluidic devices in infectious diseases and cancer.

2. Microfluidic platforms for biomarker detection

In the early stage of microfluidics, microfluidic devices were predominantly made with methods borrowed from microelectronics field and involved materials such as glass, quartz or silicon. Silicon and glass are more expensive and less flexible to work with, as compared to polymers (e.g. PMMA and PDMS). Most of them have good optical properties similar to glass, but their fabrication (e.g. soft lithography^{62–64}) does not have stringent requirements on cleanroom facility, which makes polymer-based microfluidic devices widely used. Within recent years, paper-based microfluidic devices have debuted as a lower-cost microfluidic platform.^{19, 65, 66} The choice of material depends on the research application, detection system, fabrication facility, cost and other factors such as resistance to different chemicals, thermal conductivity, dielectric strength and sealing properties. This section mainly aims to give a general introduction of various cost-effective microfluidic platforms used for disease biomarker detection. Since the focus of this article is not to review recent fabrication techniques, only common fabrication techniques and their recent advances are briefly described. A few other review articles described more details of fabrication methods for different microfluidic platforms.^{67–69}

2.1 PDMS Microfluidic Platforms

PDMS is one of the most widely used elastomers for microfluidic devices as it is optically transparent, elastic, and cures at low temperature. It can seal with itself and a range of other materials after being exposed to air plasma. The ease and low cost of fabrication and ability to be cast in high resolution add to its advantages. In contrast to other thermoplastic materials, PDMS is gas permeable, making it compatible for cell culture. Although PDMS is one of the most widely used cost-effective microfluidic platforms, there are some limitations of PDMS as well. PDMS swells in organic solvents and low molecular weight organic solutes. It cannot withstand high temperature and the mechanical resistance is quite low. There are different methods available for the fabrication of PDMS devices including soft lithography, casting, injection molding, imprinting, hot embossing, laser ablation and others.^{22, 62, 63}

Soft lithography is the most widely used method for PDMS fabrication. Soft lithography can start with creation of a photomask in a transparency film. The resolution of transparency is $>20\text{ }\mu\text{m}$ as compared to chrome mask $\sim 500\text{ nm}$.⁷¹ Photoresist is then added to the silicon wafer, and exposed to UV light through the photomask to produce a positive relief of photoresist on a silicon wafer (master). Masters can also be fabricated by techniques like etching in silicon and electroforming metal. Channels in PDMS can be formed by replica molding once a master is fabricated. The cured PDMS replica can be bonded with another flat layer of PDMS, glass or other materials to form a closed system. Based on soft lithography, Kung *et al.*⁷⁰ demonstrated a novel method for fabricating 3D high aspect ratio PDMS microfluidic networks with a hybrid stamp. Figure 1 shows the schematic of fabrication process flow. A SU8 master is treated with trichloro (1*H*,1*H*,2*H*,2*H*-perfluorooctyl)silane (PFOCTS) to facilitate subsequent demolding. An uncured PDMS mixture is then poured on the master followed by pressing against the hybrid stamp. Then, the casted PDMS film is peeled off from the master since it tends to adhere to the hybrid stamp, as there is less PFOCTS on the hybrid stamp. Afterwards, the PDMS film is transferred and bonded with glass/silicon by oxygen plasma treatment, followed with the removal of the supporting PDMS, the polystyrene plastic plate and residual PDMS. Finally, the stacking process is repeated to complete the 3D fabrication. They showed that multilayer 3D PDMS structures could be constructed and bonded between two hard substrates. As an example, they fabricated a microfluidic 3D deformable channel by sandwiching two PDMS membranes ($20\text{ }\mu\text{m}$ wide and $80\text{ }\mu\text{m}$ tall) between two glass substrates. This 3D fabrication method could be applied in electrokinetics, optofluidics, inertial microfluidics, and other fields where the shape of the channel cross-section is significant in device physics. Comina *et al.*⁷² described another method for fabrication of 3D PDMS devices using templates printed with a commercial micro-stereo lithography 3D printer with a resolution of $50\text{ }\mu\text{m}$. The process eliminates the need for clean room facilities and repeated photolithographic steps required for templates with different thickness. They reported that the templates are reusable and can be fabricated within 20 min, with an average cost of 0.48 US\$.

2.2 Thermoplastic microfluidic platforms

Thermoplastics are also being used as the substitute of glass and silicon as the microfluidic platform due to their chemical and mechanical properties. Thermoplastic devices are economical for mass production and are compatible with most chemical reagents and biological assays. Several kinds of thermoplastic have been used such as PMMA, (i.e. acrylic), polycarbonate, polyester and polyvinylchloride (PVC), because of their low-cost, desirable optical properties and ease of fabrication. They offer better performances than PDMS under mechanical stress. They don't require long fabrication and curing time. These thermoplastic devices can be fabricated easily by cutting the pattern using a CO_2 laser cutter followed by bonding with adhesive or heat to form 3D devices. Multilayer devices can be completed and become ready for testing in as little as several hours.⁷³ Cassano *et al.*⁷⁴ used vacuum bagging for thermal bonding of thermoplastic microfluidic devices. Vacuum bagging completely eliminates time constraints resulting from using solvents, adhesives, or surface treatments. With fabrication technologies including hot embossing or imprinting,^{75, 76} laser ablation,⁷⁷ injection molding⁷⁸ and soft lithography, dimensions of plastic microchannels can be achieved in the range of $15\text{--}30\text{ }\mu\text{m}$. Recently, simple methods

have been developed for rapid prototyping of thermoplastic microfluidic platforms. For example, Roy *et al.*⁷⁹ reported a rapid prototyping technique for fabrication of multilayer microfluidic device using styrenic thermoplastic elastomer (TPE). They established a proof of principle for valving and mixing with three different grades of TPE using an SU-8 master mold. Miserere *et al.*⁸⁰ proposed a strategy for the fabrication of flexible thermoplastic microdevices based on lamination process. Low-cost laminator can be used from master fabrication to microchannel sealing. They demonstrated the process using Cyclo-olefin Copolymer (COC). Rahmanian *et al.*⁸¹ described rapid desktop manufacturing of sealed thermoplastic microchannels. Patterning was achieved by simply drawing the desired microchannel pattern onto the polymer surface using suitable ink as a masking layer, followed by exposure to solvent vapor to yield a desired depth. The channels were then permanently sealed through solvent bonding of the microchannel chip to a mating thermoplastic substrate. Among these various fabrication methods, two of the most widely used fabrication techniques in the field of microfluidic biomarker detection are discussed in brief in this review.

2.2.1 Hot embossing—The hot embossing^{75, 76} or imprinting is an established method to fabricate microchannels in common polymer such as polystyrene (PS), polyethylene terephthalate glycol (PETG), PMMA, PVC, and polycarbonate. Silicon stamps are the more commonly used embossing tools for the fabrication of these polymeric microfluidic devices. A typical hot embossing setup consists of a force frame, which delivers the embossing force via a spindle and a T-bar to the boss or the embossing master. The microstructures are then transferred from the master to the polymer by stamping the master into the polymer by heating above its glass transition temperature (T_g) in vacuum.⁷⁵ Alternatively, polymer devices can be imprinted at room temperature with elevated pressure. The master structure is pressed into the thermoplastic substrate with a force (e.g. 20–30 kN in case of PMMA or PC) depending on the type and size of the substrate along with the feature to be imprinted.⁷⁵ Finally, the master and the substrate are isothermally cooled to a temperature just below T_g and then separated. The resulting plastic microchannel dimensions are the exact mirror image of the silicon stamp when devices are hot embossed.

2.2.2 Laser ablation—Laser ablation^{77, 82} is also one of the rapid prototyping methods for microfluidic devices. In this technique, the polymer is exposed to the high intensity laser beam, which evaporates the material at the focal point that is due to photo-degradation or thermal-degradation or the combination of two. Pulsed laser is typically used, so each laser shot will ablate a defined amount of material, depending on the material type and absorption properties, laser intensity, wavelength and number of passes made across the channel. This process leads to the rough surface of the laser-ablated microchannels and have a rippled appearance, which depends upon the absorption of polymer at excimer wavelength. Very high temperature is reached during ablation and particles are ejected from the substrate creating a void, with small particulates on the surface of the substrate material, while other decomposition products become gases (carbon dioxide and carbon monoxide). Laser ablation may be achieved by two ways. Polymer substrate can be exposed to a laser through a mask. A mask is usually made from the material that does not have significant absorption at the laser wavelength used. In the mask-less process, a polymer substrate is placed on a

movable stage and either the focused laser beam or the substrate is moved across in x and y direction as defined in the desired pattern.

2.3 Paper-based microfluidic platforms

Paper is a thin sheet of material that is generally produced by pressing together cellulosic or nitrocellulose fibers.⁶⁵ Paper can transport liquids via capillary effect without the assistance of external forces. Fabrication of paper-based devices is simple and does not require the use of clean-room facilities. Paper has good stackability, which allows the formation of 3D structures for complex assays. The high surface to volume ratio provided by the macroporous structure in paper improves the immobilization of protein and DNA biomarkers, allowing fast detection. Paper-based microfluidics devices can be fabricated both in 2D and 3D for either horizontal or vertical flow.⁶⁸ Fabrication of the paper-based devices can be subdivided into two categories: (i) construction of hydrophobic barriers, and (ii) two-dimensional cutting.

2.3.1 Constructing hydrophobic barriers—One of the most widely used methods to prepare paper-based analytical devices (μ PADs) is to construct hydrophobic barriers in the hydrophilic paper matrix. In this way, reagents and analytes can be made to flow in a certain path preventing mixing and spreading across the surrounding paper surface and achieve multiplexed assays without the issue of cross contamination. Hydrophobic barriers can be created on paper through either a physical deposition⁸³ or a chemical modification method.⁸⁴ A number of different fabrication methods have been developed to fabricate μ PADs, such as fast photolithography,^{85, 86} wax-based fabrication techniques,^{83, 87} printing photolithography,⁸⁸ PDMS printing,⁸⁹ saline UV/O₃ patterning⁹⁰, flexographic printing,⁹¹ and alkenyl ketene dimer (AKD) printing.⁸⁴ Examples of wax-based fabrication include wax screen-printing,⁸⁷ wax dipping,⁹² and wax printing.⁸³ In wax screen-printing,⁸⁷ solid wax is rubbed through a screen onto paper filters. The printed wax is then melted into paper so that the melted wax diffuse into paper to form hydrophobic barriers using a hot plate. In wax dipping,⁹² ironmould is first prepared by the laser cutting technique. The designed pattern is then developed into paper by transferring the pattern mould (sealed by magnets) into molten wax. Wax printing, in which the designed pattern is directly printed on paper using a solid ink (or wax) printer,⁹³ is considered to be one of the most promising and attractive wax-based methods, due to its low cost and high potential for massive production. After printing, the wax-printed paper is incubated in an oven so that the melted wax from the paper surface can penetrate into paper to form well-defined microchannels across the whole thickness of the paper-based device owing to the porous structure of the filter paper. The time required for the patterned wax on paper to penetrate through depends on the temperature used (5 min at 110 °C, 30 s at 130 °C) and the wax-patterned paper is stable when store under 60 °C.⁸³ In 2014, Sameenoi *et al.*⁹⁴ reported one-step polymer screen-printing for microfluidic paper-based devices. In this process, a polystyrene solution that is applied through the screen penetrates through the paper to form a 3D hydrophobic barrier, defining a hydrophilic analysis zone. The smallest hydrophilic channel and hydrophobic barrier obtained was found to be $670 \pm 50 \mu\text{m}$ and $380 \pm 40 \mu\text{m}$, respectively. Among these fabrication methods, photolithography and wax printing are widely used. Wax is inexpensive and non-toxic.^{83, 87, 92} Recently, paper/polymer hybrid devices have been developed (Figure 2B), but

their fabrication methods is mainly derived from a combination of paper-based and polymer microfluidic device fabrication techniques.^{41, 95}

FLASH (Fast Lithographic Activation of Sheets): One of the most widely used fabrication technology for constructing hydrophobic barriers in paper-based devices is photolithography or FLASH.⁸⁶ Chromatography paper is the commonly used substrate. FLASH requires a UV lamp, a printer and a hotplate along with photoresist such as SU-8 and other organic solvents. Figure 2A shows the procedures. In this technique⁸⁶ photoresist is first poured onto a piece of paper and spread evenly and baked on a hotplate at 130 °C for 5–10 min to evaporate propylene glycol monomethyl ether acetate (PGMEA) from the photoresist. Then, the paper is covered with a photomask and exposed to UV light. After incubation in an oven, the chromatography paper is developed in acetone, followed with rinsing with isopropyl alcohol. After drying, the paper-based device is ready to use.

2.3.2 Two-dimensional cutting—Another way to create paper-based microfluidic device is 2D cutting. Paper channels are cut through computer controlled X–Y knife plotters or CO₂ laser cutters, and then fixed to suitable plastic cassettes to form hybrid devices.^{96, 97} Nitrocellulose, conventional photocopy paper and chromatography paper can be used. Thuo *et al.*⁹⁷ described the use of embossing and a “cut-and-stack” method to develop microfluidic devices from omniphobic paper. They demonstrated that fluid flow in these devices was similar to open-channel microfluidic devices and cut layer generated 3D systems.

3. Biomarker detection methods for disease diagnosis using microfluidic devices

Wide ranges of detection methods have been employed for the detection of a number of disease biomarkers in microfluidic devices, as summarized in Table 1. Colorimetric, fluorescent and electrochemical detection remain the most widely used ones. Nevertheless, detection mechanism such as chemiluminescence, electrochemiluminescence and other detection mechanisms have also been applied to disease biomarker detection.

3.1 Colorimetric Detection

Colorimetric detection is generally carried out based on the color change of the detection system resulted from chemical/biochemical reactions between target analytes and colorimetric probes.⁹⁸ The major advantage of the colorimetric assay is that it doesn't rely on bulky off-chip detection system, thus allowing naked-eye-based readout methods.⁹⁹ Therefore, colorimetric detection has attracted increasing research interest in the biomedical field especially for disease diagnosis due to its unique advantages for POC detection of infectious diseases.^{100–103} The summary from Table 1 shows that colorimetric detection is less widely used in cancer biomarker detection.

Many researchers have made incredible advances in the field of colorimetric detection methods. Wide ranges of biomolecules from protein biomarkers for infectious diseases to glucose and nucleic acids have been studied using colorimetric detection. For instance, Yu *et*

*al.*³⁹ reported a PDMS microfluidic chip for ELISA. The PDMS platform was modified with dextran to increase the hydrophilicity and to covalently immobilize proteins on the surface of PDMS. The colorimetric immunoassay in the modified PDMS microfluidic device was used to simultaneously detect multiple important biomarkers, Interleukin-5 (IL-5, a biomarker for bronchial asthma), Hepatitis B surface antigen (HBsAg, a biomarker for Hepatitis B virus) and Immunoglobulin G (IgG, a biomarker for Neuromyelitis optica). 3,3', 5,5'-Tetramethylbenzidine (TMB) was used as the substrate for Horseradish peroxidase (HRP) labelled secondary antibody. The chip allowed reaching a limit of detection (LOD) of 100 pg/mL and a dynamic range of 5 orders of magnitude. Covalent immobilization of protein can increase the specificity and sensitivity of the device. Yu *et al.*¹⁰⁴ described UV-curable epoxy resin based microarray and immunoassay device, using PDMS mold, and taking advantages of the functional epoxide group for efficient protein immobilization. The LOD was 10 pg/mL for IgG and 100 pg/mL for IL-5, using TMB as the enzyme substrate. Most of the reported microfluidic devices did not integrate on-chip raw sample processing. Park *et al.*¹⁰⁵ showed Lab-on-a-disc for fully integrated multiplexed immunoassay from raw samples such as whole blood and whole saliva. Biomarkers for cardiovascular disease were detected in this centrifugal PMMA microfluidic layout. Reaction chambers were initially interconnected for sample injection, incubation and washing after which they were isolated for substrate incubation and detection. TMB was used as a substrate for HRP-conjugated antibody and detected by using the built-in LED and the photodiode. The LOD was found to be 0.30, 0.51, and 0.24 ng/mL for high-sensitive C-reactive protein (hsCRP), cardiac troponin I (cTnI), and N-terminal pro-B type natriuretic peptide (NT-proBNP), respectively. Additionally, Fang *et al.*¹⁰⁶ showed that loop mediated isothermal amplification (LAMP) of nucleic acid of Pseudorabies virus (PRV) integrated in an eight-channel PDMS microfluidic chip. Results could be viewed by the naked eye for insoluble pyrophosphate, a byproduct, or by absorbance, which was measured by optical sensors (high-intensity red light-emitting diode (LED) light at 640 nm and a phototransistor). The assay, which could be completed within an hour, had the LOD of 10 fg/ μ L of DNA samples.

Colorimetric results can either be observed by the naked eye or analyzed by software installed on a desktop computer or by applications on mobile phones. For instance, Wang *et al.*¹⁰⁷ developed a tree-shaped paper strip for semiquantitative colorimetric detection of protein with self-calibration. The approach was validated with bovine serum albumin (BSA) in artificial urine samples with colorimetric detection. They tested a range from 0 to 5 mg/mL and the concentration as low as 0.08 mg/mL could be detected using Bromophenol blue (BPB) as the indicator. Results were analyzed either from comparison of the color by the naked eyes or from measuring the intensities in the standard curve from the software Quantity One. Recently, Ahmed *et al.*¹⁰⁸ showed power-free enzyme immunoassay for detection of Prostate specific antigen (PSA), a biomarker for prostate cancer. Magnetic nanoparticles capture the target and move through chambers having reagents for ELISA. The colour change of an HRP-substrate [ABTS (2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt)] in the PMMA based device could be imaged through a smartphone camera and analyzed using Matlab®. The LOD for PSA in serum samples was found to be 3.2 ng/mL.

Multiple indicators have also been used for multiplexed assay. For example, Dungchai *et al.*¹⁰⁹ reported the use of multiple indicators on μ PAD. The oxidation of indicators by hydrogen peroxide produced by oxidase enzymes specific for each analyte gives an extended range of operation. To show the effectiveness of the approach, the mixture of 4-aminoantipyrine and 3,5-dichloro-2-hydroxy-benzenesulfonic acid, o-dianisidine dihydrochloride, potassium iodide, acid black, and acid yellow were chosen as the indicators for simultaneous semi-quantitative measurement of glucose, lactate, and uric acid on a μ PAD. They quantified glucose (0.5–20 mM), lactate (1–25 mM), and uric acid (0.1–7 mM) in clinically relevant ranges. The determination of glucose, lactate, and uric acid in control serum and urine samples were performed to demonstrate the applicability of this device for biological sample analysis. Jokerst *et al.*³⁸ developed a paper-based analytical device for detection of food borne pathogens. Detection was achieved by measuring the color change when an enzyme associated with a pathogen of interest reacts with a chromogenic substrate (β -galactosidase with chlorophenol red β -galactopyranoside (CPRG) for *Escherichia coli*; phosphatidylinositol specific phospholipase C (PI-PLC) with 5-bromo-4-chloro-3-indolyl-myo-inositol phosphate (X-InP) for *Listeria monocytogenes*; and esterase with 5-bromo-6-chloro-3-indolyl caprylate (magenta caprylate) for *Salmonella enterica*). The concentration of 10 cfu/cm² of the target bacterial species was detected within 8, 10, and 12 h of enrichment for *S. typhimurium*, *E. coli* O157:H7, and *L. monocytogenes*, respectively.

Different kinds of nanoparticles have been used in colorimetric detection to increase the sensitivity of the assay. Good optical properties, controlled synthesis and easy surface conjugation make AuNPs one of the most attractive materials for biosensing. Lei *et al.*¹¹⁰ developed a colorimetric immunoassay chip based on gold nanoparticles (AuNPs) and gold enhancement for amplifying the specific binding signal. The antibody-biotin conjugate were directly immobilized on a 3-aminopropyltriethoxysilane (APTES)-glutaraldehyde modified glass surface. AuNPs were bound to antibodies through biotin-streptavidin linkage. In gold enhancement process, gold ions in a solution were catalytically deposited onto the AuNPs and aggregated to metallic gold precipitations. Color intensity was mapped to the concentration of immobilized antigen (IgG) in a dynamic range of 1–5,000 ng/mL. Liang *et al.*¹¹¹ developed a paper-based microfluidic colorimetric immunodevice based on the Pd/Fe₃O₄@C NPs and flower-like AuNPs for multiplexed colorimetric immunodetection. In the sandwich-type immunodevice, AuNPs were utilized to immobilize primary antibodies on paper sensing zones, while Pd/Fe₃O₄@C NPs-labelled secondary antibodies were employed as the effective peroxidase mimetics to catalyse the chromogenic reactions (TMB and o-phenylenediamine as chromogenic substrates). The microfluidic immunodevice showed good colorimetric response to multiple cancer biomarkers with low limits of detection of 1.7 pg/mL for carcinoembryonic antigen (CEA) and α -fetoprotein (α -AFP). Ornatska *et al.*⁵⁴ used redox nanoparticles of cerium oxide as the chromogenic indicator for the colorimetric detection of glucose. Filter paper was first silanized with aminopropyltrimethoxysilane (APTMS), before cerium oxide nanoparticles and glucose oxidase were co-immobilized. In the presence of glucose, the enzymatically-generated hydrogen peroxide induced a colorimetric change of nanoparticles from white-yellowish to dark orange (Figure 3A).⁵⁴ The method involves two enzymatic reactions. In the first step H₂O₂ is released when the oxidase enzyme oxidizes substrate. In the second step, H₂O₂ is coupled with HRP and the

ceria nanoparticles to generate a color change. Hydroxylated Ce^{4+} forms a reddish-orange complex with H_2O_2 with maximum absorbance at 465nm. They also demonstrated the detection of glucose in human serum samples. The LOD of 0.5 mM glucose and the linear range from 2.5–100 mM were achieved using the colorimetric detection. The bioassay platform could be stored for at least 79 days at room temperature and be reused for 10 consecutive measurement cycles with the same analytical performance. Kumar *et al.*¹¹² developed a paper-based microfluidic colorimetric device for the detection of uric acid that is associated with several diseases such as diabetes, kidney disease and heart disease. In this microfluidic device, positively charged AuNPs embedded in the device were employed to facilitate the reaction between TMB and H_2O_2 to produce a clear colour change. It was found that the colorimetric method could detect uric acid at a concentration as low as 8.1 ppm. Baeissa *et al.*¹¹³ showed DNA-functionalized monolithic hydrogels and AuNPs for colorimetric DNA detection. Acrydite-modified DNA was covalently functionalized to the polyacrylamide hydrogel during gel formation. By using the attached AuNPs to catalyze the reduction of Ag^+ , the concentration as low as 1 pM target DNA could be detected. In addition, Wang *et al.*¹¹⁴ fabricated an integrated microfluidic device utilizing vancomycin-conjugated magnetic beads to capture multiple strains of bacteria and nanogold-labelled specific nucleotide probes for colorimetric PCR-free pathogen detection. Microfluidic device had suction-type micropumps, microvalves, microchannels, and microchambers for complete automation. The LOD of the PDMS microdevice was found to be 10^2 CFU/mL of *E. coli*.

3.2 Fluorescent Detection

The availability of highly sensitive and selective fluorescent labeling techniques makes fluorescence one of the most widely used optical methods for biomolecular sensing in microfluidic systems. A fluorescent dye, is a small molecule, protein or a quantum dot, which emits photon after being excited and can be used to label proteins, nucleic acids, or lipids. The detection requires excitation light, fluorescent dyes (if no intrinsic fluorescence), multiple filters, and a detector to record emitted photons. Compared to colorimetric detection, one of the drawbacks of fluorescence detection is that fluorescence optical detection system is fairly complex and bulky.

Detection of protein biomarkers for infectious diseases and cancer are some of the different application areas where fluorescence detection has been utilized. Lee *et al.*⁴² reported a PDMS microfluidic system utilizing virus-bound magnetic bead complexes for the detection of infections by the dengue virus by simultaneous rapid detection of immunoglobulin G (IgG) and immunoglobulin M (IgM). IgG and IgM in serum samples were captured by virus-bound magnetic beads.⁴² The interfering substances in the biological substances were washed away, after which the fluorescence-labeled secondary antibodies were bound to the surface of the IgG/IgM complex attached onto the magnetic beads. The target IgM and IgG were recognized by the specific attached antibodies (anti-human IgG antibody labeled with fluorescein isothiocyanate (FITC) and anti-human IgM antibody labeled with R-phycoerythrin (R-PE)). The optical signals were then measured and analyzed by a real-time optical detection module. The LOD for IgG was shown to be 21 pg/mL. Mohammed *et al.*⁵⁰ demonstrated a PMMA based autonomous capillary microfluidic system with embedded

optics for detection of cTnI, a cardiac biomarker. They used CO₂ laser engraving for rapid prototyping of the capillary system with on-chip planar lenses and bio-sensing elements. The fluoro-immunoassay was done in modified PMMA using fluorescein isothiocyanate (FITC). The fluorescence excitation and detection instrumentation was simple, which was palm-sized and battery powered. The LOD was found to be 24 pg/mL. Diercks *et al.*¹¹⁵ developed a PDMS microfluidic device for multiplexed protein detection in a nano-liter volume. Chip had optically encoded microspheres to create an array of approximately 100- μm^2 sensors functionalized with capture antibodies directed against distinct targets. The sensitivity of the device was sufficient to detect 1000 copies of tumor necrosis factor (TNF) in a volume of 4.7 nL. Castro-López *et al.*¹¹⁶ developed a portable device for the quantification of TNF- α in human plasma with fluorescence detection using the dye fluorescein amidite (FAM). They performed magnetic bead-based proximity ligation assay (PLA) where probes were immobilized onto streptavidin-coated magnetic beads. The cyclo-olefin polymer based device interfaced with a quantitative real-time PCR device developed in-house, had an assay time of 3 h with the LOD of 3.1 pg/mL.

Hybrid microfluidic devices that can draw benefits from multiple device substrates have also been developed for the detection of pathogens. Li and his co-workers⁹⁵ developed the first PDMS/paper hybrid microfluidic biochip for one-step multiplexed pathogen detection with aptamer-functionalized grapheme oxide nano-biosensors (see Figure 3B). When the Cy3-labeled fluorescent aptamer is adsorbed on the surface of chromatography paper disks inside PDMS microwells, the fluorescence is quenched by graphene oxide (GO) (Figure 3B3).⁹⁵ In the presence of a target pathogen, the target pathogen induces the aptamer to be liberated from GO and thereby restores its fluorescence for detection. The novel use of paper in this hybrid systems facilitated facile nanosensor immobilization on the chip, which avoided complicated surface modification to immobilize nanosensor in non-hybrid microfluidic platforms. The PDMS/paper hybrid microfluidic platform was used for the detection of *Lactobacillus acidophilus* with the LOD of 11.0 colony forming unit (cfu)/mL. The hybrid microfluidic biochip was further used for simultaneous detection of two infectious pathogens, *S. aureus* and *S. enterica* with high specificity (Figure 3B4). Recently, Dou *et al.*⁴¹ reported a PDMS/paper hybrid microfluidic platform integrated with loop-mediated isothermal amplification (LAMP) for instrument-free infectious disease diagnosis with high sensitivity. As shown in Figure 2B, the chip consists of one top PDMS layer, one middle PDMS layer, and one glass slide for reagent delivery, LAMP reaction, and structure support, respectively. A chromatography paper disk was placed inside each LAMP zone for preloading LAMP primers. It was found that the use of paper in this hybrid system enabled longer shelf life time of the hybrid microfluidic platform than a paper-free platform. When a positive sample is shined by a potable UV light pen, bright green fluorescence from calcein can be observed by the naked eye, or imaged by a cell phone camera. The limit of detection of *N. meningitidis* was found to be 3 copies per LAMP zone within 45 min, comparable with that of real-time PCR.¹¹⁷ This kind of hybrid microfluidic devices can draw more benefits from both substrates, and avoid limitations from individual chip substrates. Jing *et al.*¹¹⁸ developed a PMMA/PDMS hybrid microfluidic device for efficient airborne bacteria capture and enrichment. The device had two PDMS plates sandwiched by two plates of PMMA using four screws for structural support. Chaotic vortex flow created in the PDMS

channel by the staggered herringbone mixer (SHM) resulted in high capture and enrichment as confirmed by flow dynamic mimicking. They showed that the efficiency reached close to 100% in 9 min. The device was validated using *E. coli* and *Mycobacterium smegmatis*. Bacterial cells were quantified with green fluorescence, when exposed to blue light. In addition, Wang *et al.*⁶¹ developed a portable PMMA/glass hybrid microfluidic immunochip for detecting *E. coli* in produce and milk. The PMMA and glass plates were assembled with double-sided adhesive tape and the microchannels were functionalized using Protein G and NeutrAvidin based methods. Captured bacteria were imaged using an inverted fluorescence microscope through a GFP fluorescence filter. The LOD was found to be 50, 50, 50, and 500 CFUs/mL for PBS, blood, milk, and spinach, respectively.

Microfluidic droplets can act as microfluidic bioreactors for enzymatic amplification that has been used to increase the sensitivity of fluorescence detection. For example, Joensson *et al.*¹¹⁹ described a method for the detection and analysis of low-abundance cell-surface biomarkers using enzymatic amplification inside the microscopic droplets within a microfluidic device. Cells were labeled for cell-surface biomarkers with biotinylated antibodies to bind streptavidin-coupled β -galactosidase. The enzyme labeled cell stream was merged with a fluorogenic substrate (fluorescein-di- β -d-galactopyranoside, FDG) in the device. The fluorescence of individual droplets was quantified using laser-induced fluorescence (500–1500 droplets per second). They demonstrated detection of the low-abundance biomarkers CCR5 (a co-receptor in HIV-1 infection) and CD19 (a B-cell lineage marker) from single human monocytic (U937) cells. Recently, Lin *et al.*¹²⁰ demonstrated bubble-driven mixer that was integrated to a microfluidic device for bead-based ELISA to detect bladder cancer. They used a wooden gas diffuser to generate bubbles less than 0.3 mm. The micromixer reduced the time for incubation from 60 min to 8 min, so that ELISA reaction time was reduced to 30–40 min. A fluorescent dye, FITC-streptavidin complex was used in this PDMS device, wherein magnetic beads were used to coat the primary antibody. Apolipoprotein A1 (APOA1), a biomarker highly correlated with bladder cancer was detected with the LOD of 9.16 ng/mL, which was lower than the detection cut-off value of 11.16 ng/mL.

It has always been a great challenge to capture and analyse a small number of circulating tumor cells (CTCs) from a large pool of cancer samples. Riahi *et al.*¹²¹ developed a cyclic olefin polymer (COP) microfluidic device that uses a size and deformability-based capture system to capture and analyse CTCs of breast cancer. The device selects and segregates the CTCs in their own chamber, thus enabling morphological, immunological and genetic characterization of each CTC at the single cell level. Immunostaining of different breast cancer biomarkers was used to further characterize differential expressions of the captured cells. AlexaFlour 488 conjugated antibodies against either vimentin or E-cadherin were used for staining. Nuclei were counterstained with Hoechst-33342. The efficiency of cell capturing ranged between 75–83% for MCF7, 77–85% for MDA-MB-231 and 78–89% for SKBR3 in a range of cells from 20–2,000. Their result showed that the microfluidic device captured both epithelial cancer cells such as MCF7 and SKBR3 and epithelial to mesenchymal transition (EMT)-like cells such as MDA-MB-231. Immunostaining of captured cells in microchannel devices helped to identify differential expressions and

phenotypes of captured cells using panel of epithelial and mesenchymal breast cancer biomarkers.

Quantum dots (QDs) have advantages over conventional dye molecules such as tunable fluorescence signatures, narrow emission spectra, brighter emission, and good photostability. Use of QDs as a fluorogenic dye can help increase the sensitivity of the assay. Hu *et al.*¹²² developed a PDMS microfluidic protein chip for multiplexed assay of cancer biomarkers using aqueous-phase-synthesized CdTe/CdS quantum dots (aqQDS) as fluorescent signal amplifiers. Secondary antibodies were conjugated to luminescent CdTe/CdS QDs as the fluorescent probe. They showed that their microfluidic protein chip possessed femtomolar sensitivity for cancer biomarkers and was selective enough to be directly used for two biomarkers detection in serum. The LODs were estimated to be 250 fM for both carcinoma embryonic antigen (CEA, a biomarker for colorectal carcinoma) and α -fetoprotein (AFP, a biomarker for hepatocellular carcinoma). Similarly, Zhang *et al.*¹²³ developed PDMS beads-based microfluidic immunosensor using multienzyme-nanoparticle amplification and quantum dots labels. Microbeads were functionalized with capture antibodies and modified electron rich proteins within microfluidic channels. AuNPs were functionalized with multi-HRP-antibody for enhanced sensitivity. In addition, streptavidin-labeled quantum dots were bound to the deposited biotin moieties as the signal probe. Dual signal amplification resulted in the LOD of 0.2 fg/chip for AFP. Yu *et al.*¹²⁴ developed another PDMS microfluidic chip based on self-assembled magnetic bead pattern and quantum dots for cancer biomarker detection in serum. High magnetic field gradient was generated using nickel pattern to increase the magnetic force on the superparamagnetic beads (SPMBs), which was stable during fast continuous washing. Fast continuous washing could remove non-specifically adsorptive contaminants more efficiently than fixed volume batch washing, increasing the specificity. Streptavidin modified QDs were used as fluorescence indicator to obtain the LOD of 3.5 ng/mL and 3.9 ng/mL for CEA and AFP, respectively.

Upstream sample processing is often a limiting step in the microfluidic devices. Hoffman *et al.*¹²⁵ demonstrated a microfluidic immunoassay with biomarker purification and enrichment. They utilized stimuli-responsive polymer-antibody conjugates for sample processing in the circular microreactor with transverse flow generators to purify and concentrate the PSA sandwich immunocomplexes. Poly (N-isopropylacrylamide) (PNIPAAm), a thermally responsive polymer was covalently grafted to the lysine residues of anti-prostate specific antigen (an Immunoglobulin G). The antibody-PNIPAAm conjugate and antibody-alkaline phosphatase conjugate formed sandwich immunocomplex via PSA binding. Samples were loaded into the device and heated to 39°C above which immunocomplexes separates from human plasma solution by immobilizing through hydrophobic interactions. 4-methylumbelliferyl phosphate (4-MUP) was used as the fluorescence substrate for the alkaline phosphatase conjugated antibody in the PDMS device. For subsequent separation, enrichment, and quantification, these complexes were loaded into a recirculating PDMS bioreactor, which was equipped with micropumps, and transverse flow features. In order to enrich immunocomplexes within the recirculator, the loading, washing, and mixing steps were repeated for a total of three times. The assay which took 25 min had the LOD of 37 pM PSA. By repeating the capture process for three times

for immunocomplex enrichment, the LOD of 0.5 pM was obtained. As shown in Table 1, this is much lower than the LOD from colorimetric detection.¹⁰⁸

3.3 Electrochemical Detection

Electrochemical detection involves interaction of chemical species with electrodes or probes to obtain electrical signals, such as potential or current, enabling quantitative analysis of target analytes. Either a chemical reaction is promoted by passing an electrical current through the electrode system or electrode responses are triggered due to specific chemical reactions (oxidation and reduction). A typical electrolytic cell consists of a working electrode where detection of a certain analyte is analyzed, a reference electrode where a standard oxidation/reduction is conducted and a counter electrode to minimize the electrical current flowing through the reference electrode, thus maintaining its potential constant during the operation of the electrolytic cell. Recently, incorporation of electrochemical detection in paper-based microfluidic devices has led development of easy-to-use, low cost, portable diagnostic devices with high sensitivity and selectivity by proper choices of detection potential and/or electrode materials, as shown by many reports of paper-based electrochemical systems listed in Table 1. Microfluidic channels can be fabricated on cellulose paper using different techniques mentioned before, while electrodes can be fabricated on paper by methods including screen-printing, direct-writing with a pen/pencil dispensing conductive material, physical deposition of metals, and spraying conductive inks through stencils.¹²⁶ However, screen-printing approach remains the most common technique for electrode fabrication.¹²⁷

In recent years, great efforts have been devoted for the development of electrochemical detection-based microfluidic devices for disease diagnosis especially for the detection of cancer biomarkers and infectious diseases.^{128, 129} Li *et al.*¹³⁰ described an electrochemical ELISA on paper-based microfluidic devices. Paper-based microfluidic devices were fabricated by patterning chromatography paper using the photolithography technique. Working and counter electrodes were screen-printed from graphite ink, and a reference electrode from silver/silver chloride ink. The electrochemical ELISA of IgG based on cyclic voltammetry (CV) was demonstrated with the LOD of 3.9 fM. Wu *et al.*³¹ developed a microfluidic paper-based electrochemical immunodevice integrated with amplification-by-polymerization for multiplexed detection of cancer biomarkers by using differential pulse voltammetry (DPV) method. In this work, the paper-based immunodevice was prepared based on the photoresist-patterning technique (Figure 4).³¹ Eight working electrode zones were screen-printed with carbon ink in a specific area on paper-A. In the same manner, carbon ink and Ag/AgCl ink were screen-printed on a predesigned area of paper-B as the counter electrode and the reference electrode, respectively. Eight working electrodes shared one pair of counter and reference electrodes after the two paper layers were stacked together (Figure 4A). GO was modified on the working electrode to construct the sandwiched immuno-structure (Figure 4B). Four cancer biomarkers, namely carcinoembryonic antigen (CEA), AFP, cancer antigen 125 (CA-125, a biomarker for ovarian cancer), and carbohydrate antigen 153 (CA153, a biomarker for breast cancer) were detected by using the HRP-O-phenylenediamine-H₂O₂ electrochemical system. The LODs were found to be 0.01 ng/mL, 0.01 ng/mL, 0.05 ng/mL, and 0.05 ng/mL, respectively. Chikkaveeraiah *et al.*⁴⁹

reported a microfluidic electrochemical immunoassay for multiplexed detection of cancer biomarkers using a molded PDMS channel and routine machined parts interfaced with a pump and sample injector. The LODs of 0.23 pg/mL for PSA and 0.30 pg/mL for Interleukin 6 (IL-6) were obtained in diluted serum mixtures. In addition, Su *et al.*⁵⁵ developed a paper-based microfluidic electrochemical cyto-device (μ -PECD) for cancer cell detection and in situ screening of anticancer drugs in a multiplex manner based on in-electrode 3D cell culture. This entire μ -PECD was fabricated on a single sheet of flat paper. The LOD for HL-60 (human acute promyelocytic leukemia) cell was calculated to be 350 cells/mL using fast-response DPV method. Furthermore, in situ anticancer drug screening was successfully implemented in this μ -PECD. Sun *et al.*¹³¹ presented a paper-based microfluidic electrochemical immunosensor for CEA detection based on 3D flower-like gold electrode and gold-silver bimetallic nanoparticles. The LOD was found to be 0.3 pg/mL using an amperometric method.

The physical adsorption may result in strong non-specific binding.¹³² Hence, device surfaces can be modified for the covalent immobilization of antibodies to increase the sensitivity for immunoassay of biomarkers. Wang *et al.*³³ demonstrated an electrochemical immunoassay on a wax-patterned paper-based 3D microfluidic electrochemical device (3D- μ PED) using a DPV method. Paper pre-coated with chitosan and cross-linked with glutaraldehyde was used to immobilize antibodies for CA-125 and CEA. The multi-walled carbon nanotubes (MWCNTs)-modified μ PAD could detect two tumor markers simultaneously in real clinical serum samples with linear ranges of 0.001–75.0 U/mL for CA-125 and 0.05–50.0 ng/mL for CEA. The LODs for CA-125 and CEA were 0.2 mU/mL and 0.01 ng/mL, respectively. Liu *et al.*¹³³ developed a PMMA microfluidic chip coupled with three-electrode electrochemical detection system to detect trace level of AFP. For covalent immobilization of AFP monoclonal antibody, PMMA microchannels were first modified with poly (ethyleneimine). The captured analyte, AFP, was finally bound with HRP-conjugated AFP antibody for electrochemical detection. When the substrate mixture of 2-amino hydroxybenzene and hydrogen peroxide was pumped into the PMMA microchannel, the HRP enzyme labeled on the AFP antibody within microchannels would instantaneously catalyze the substrate, and the generated electroactive 3-amino phenoxazine was detected using differential pulse voltammetry (DPV). The immunochip had the LOD of 1 pg/mL for AFP with a detectable linear concentration range of 1–500 pg/mL. AFP existing in healthy human serum was detected to demonstrate the application of the immunochip.

Cardiovascular disease is one of the leading causes of death in the world. Multiple microfluidic electrochemical systems were developed to measure heart disease biomarkers. Zhou *et al.*¹³⁴ developed an electrochemical immunoassay for the simultaneous detection of cardiac cTnI and c-reactive protein (CRP) on a PDMS microfluidic chip. Cardiac troponin I is used to diagnose acute myocardial infarction. C-reactive protein (CRP) is used in the risk assessment of coronary events and in optimizing therapy in the primary and secondary prevention settings of cardiovascular diseases. The methodology was based on ELISA performed in PDMS-gold nanoparticle composite microreactors. Sandwich immunoassay was done by bioconjugating CdTe and ZnSe quantum dots. Cd²⁺ and Zn²⁺ were detected by square-wave anodic stripping voltammetry for quantification of the two biomarkers. The immunosensor could simultaneously detect cTnI and CRP in the linear ranges between

0.01–50 µg/L and 0.5–200 µg/L respectively. They showed that the limits of detection were 5 amol and 307 amol in a 30 µL sample corresponding to cTnI and CRP, respectively. Liang *et al.*¹³⁵ developed a microfluidic electrochemical immunoassay for the detection of heart failure markers amino-terminal pro-brain natriuretic peptides (NT-proBNP) in whole blood with the LOD of 0.03 ng/mL. Magnetic nanoparticles and the biotin-avidin system were employed in the microfluidic device to fabricate the regeneration-free electrochemical immunosensor. Recently, Horak *et al.*⁴³ presented a polymer-modified microfluidic immuno chip for enhanced electrochemical detection of a cardiac biomarker, troponin I. The combination of a disposable microfluidic immuno chip fabricated in a Vacrel® 8100 photoresist film and surface functionalization by polyethylenimine (PEI) was utilized to construct the microfluidic device. A 18-fold improvement of the LOD and 2.5 times faster read-out time in comparison to the assay without the PEI coating were achieved with the LOD of 25 pg/mL.

Microfluidic electrochemical devices have also been used for the detection of other important biomarkers. Medina-Sánchez *et al.*⁴⁵ reported an electrochemical assay for apolipoprotein E (ApoE, a biomarker of Alzheimer's disease) using cadmium-selenide/zinc-sulfide quantum dots as the labeling carrier. The electrochemical detector consisted of a set of three electrodes produced by screen-printing with a micro-potentiostat. A PDMS film was bound to APTES modified PC substrate after plasma treatment for irreversible bonding. Tosylactivated magnetic beads were used as a pre-concentration platform for the immunoassay. The use of a microchannel with a magnetic retention zone allowed the sample purification and pre-concentration using magnetic beads as stationary support, providing good sensitivity and control. Electrochemical detection was obtained by square wave anodic stripping voltammetry. The limit of detection was found to be 12.5 ng/mL with a linearity range from 10 to 200 ng/mL. Zhao *et al.*¹³⁶ reported a paper-based microfluidic electrochemical array for multiplexed detection of metabolic biomarkers. An array of eight electrochemical sensors and a handheld custom-made electrochemical reader for signal readout were employed in the device for the simultaneous detection of glucose, lactate and uric acid in urine with the limits of detection of 0.35 mM, 1.76 mM, and 0.52 mM, respectively. Recently, Ben-Yoav *et al.*¹³⁷ illustrated a controllable PDMS microfluidic electrochemical method for label-free analysis of DNA hybridization in diagnosis of genetic disorders. The theoretical LOD was found to be 1 nM of complementary ssDNA target using CV method.

3.4 Chemiluminescence detection

Chemiluminescence (CL) is another optical detection method for analyte detection in which target binding leads to certain chemical reactions to cause photochemical emission, either directly or with the help of an enzyme label. CL detection systems may be more convenient for point-of-care setting, because this technique does not require excitation light source and emission filters as compared to fluorescence detection. However, the development of low-cost photodetectors is still necessary for its wide application in POC settings.^{138,139}

Chemiluminescence detection of various cancer biomarkers has been achieved in different microfluidic platforms. Wang *et al.*³² described a paper-based microfluidic

chemiluminescence ELISA. The μ PAD was fabricated by wax-screen printing method and modified with chitosan. Luminol-*p*-iodophenol- H_2O_2 solution used as the substrate for HRP-CL. Chemiluminescence ELISA showed the linear ranges of 0.1–35.0 ng/mL for AFP, 0.5–80.0 U/mL for CA-125 and 0.1–70.0 ng/mL for CEA. The LODs were found to be 0.06 ng/mL, 0.33 ng/mL, and 0.05 ng/mL for AFP, CA-125, and CEA, respectively. Ge *et al.*¹⁴⁰ developed 3D Origami paper-based analytical device for multiplexed chemiluminescence immunoassay. Blood plasma separation from whole blood and rinse steps were integrated into the device. Ag nanoparticles were used to catalyze typical luminol- H_2O_2 CL system. The LODs for simultaneous detection of four tumor biomarkers AFP, CA 153, CA 199, and CEA were found to be 1 ng/mL, 0.4 U/mL, 0.06 U/mL, and 0.02 ng/mL, respectively. In addition, chemiluminescence has also been used to study human thyroid stimulating hormone. Matos Pires *et al.*¹⁴¹ developed an HRP-luminol-peroxide-based chemiluminescence biosensor using an integrated polycarbazole photodiode as the detector. Chemiluminescence immunoassay was performed in a PDMS-gold-glass microfluidic chip. Human thyroid stimulating hormone was detected with a linear range from 0.03 to 10 ng/mL and the LOD was found to be 68 pg/mL.

AuNPs were utilized in microfluidic CL detection to enhance the detection sensitivity. For instance, Liu *et al.*¹⁴² showed chemiluminescence detection of rare cells based on aptamer-specific capture in PDMS microfluidic channels. Biotinylated aptamers were immobilized in the channel by the strong adsorption of avidin to the glass surface and then the avidin-biotin system (Figure 5A).¹⁴² Specific cells (CCRF-CEM cell line (CCL-119, T cell line, human acute lymphoblastic leukemia) and Ramos cell line (CRL-1596, B cell line, human Burkitt's lymphoma)) from a cell mixture were captured and isolated by aptamers immobilized microfluidic channel. CL reaction was then triggered by the addition of AuNPs modified with aptamers to bind to the cells. Based on the luminol- H_2O_2 -AuNPs CL reaction, CL signal could be detected when a luminol- H_2O_2 solution was pumped into the microfluidic channel. A PMT was placed directly underneath the PDMS microfluidic channel for CL detection. A low LOD of 30 target cells in a 3 μL cell mixture was obtained. Spiked whole blood samples were also used to verify the practicality of the method for inexpensive and rapid CL detection. Yang *et al.*¹⁴³ described gold nanoparticle enhanced chemiluminescence immunosensor for the detection of Staphylococcal Enterotoxin B (SEB), which is a major cause of foodborne disease. Anti-SEB antibody-gold nanoparticle complex was immobilized on a polycarbonate surface and detected by a sandwich immunoassay. Signal was detected by using a portable detector based on a cooled CCD sensor or a plate reader, and the LOD was found to be 0.01 ng/mL.

Microfluidic microarrays have also been used for high-throughput chemiluminescence detection. Zhao *et al.*¹⁴⁴ developed a low-cost 1536 chamber microfluidic microarray for mood-disorder-related serological studies. In the pilot study they quantified 384 serological biomarkers. The device was modeled similar to 1536-well microtiter plate for measuring chemiluminescence immunoassay (SuperSignal® as a substrate) using a microplate reader. The modified PMMA platform showed a similar LOD as standard ELISA but with reduced operation time (1/2 h). Matos Pires *et al.*⁵¹ developed a PMMA microfluidic biosensor array for multiplexed detection of pathogens. Organic blend heterojunction photodiodes were integrated for chemiluminescence. *E. coli*, *Campylobacter jejuni* and adenovirus were

targeted in the PMMA chip, and detection of captured pathogens was conducted by using poly (2,7-carbazole)/fullerene organic photodiodes (OPDs). Chemiluminescence signal was obtained from SuperSignal® chemiluminescence reagents added onto the streptavidin-HRP conjugate. The LOD was found to be 5×10^5 cells/mL for *E. coli*, 1×10^5 cells/mL for *C. jejuni*, and 1×10^{-8} mg/mL for adenovirus.

3.5 Electrochemiluminescence detection

ECL detection combines electrochemical and luminescence techniques that can provide good selectivity and sensitivity wherein a set of electrodes is used to trigger and control a chemiluminescence reaction involving an ECL active luminophore compound.¹⁴⁵ ECL has been widely applied in microfluidic analytical methods for biomarker detection for disease diagnosis due to its unique advantages. The outstanding advantage is its versatility and simplified optical setup compared to photoluminescence, and good temporal and spatial control compared to chemiluminescence. It does not require a bulky light source like fluorescence detection and can be generated on an electrode on a chip. Additionally, the background signal is negligible, thereby allowing optical detectors to be used at their maximum sensitivity. As summarized in Table 1, there has been a recent interest in paper-based ECL sensors.

Among various applications of microfluidic ECL biomarker detection,¹⁴⁶ the detection of cancer biomarkers for cancer diagnostics has been the subject of great research interest, as shown in Table 1. Ge *et al.*¹⁴⁷ reported a 3D microfluidic paper-based ECL immunodevice for multiplexed measurement of tumor biomarkers. In this work, a wax-patterned paper-based device using the typical tris-(bipyridine)-ruthenium (II)-tri-n-propylamine ECL system was reported. The LODs were found to be 0.15 ng/mL, 0.6 U/mL, 0.17 U/mL, and 0.5 ng/mL for AFP, CA-125, CA-199, and CEA, respectively. Yang *et al.*¹⁴⁸ fabricated a paper-based microfluidic pen-on-paper ECL (PoP-ECL) immunodevice for POC determination of CA-199 with the LOD of 0.0055 U/mL. The PoP-ECL device was constructed with a hydrophilic paper channel and two PoP electrodes with a rechargeable battery as the constant-potential power supplier to trigger the ECL. Sardesai *et al.*³⁶ described a PMMA/PDMS microfluidic ECL device for detecting cancer biomarker proteins, PSA and IL-6 in serum (Figure 5B).³⁶ The microfluidic system employed three PDMS channels on a conductive pyrolytic graphite chip (2.5×2.5 cm) inserted into a machined chamber and interfaced with a pump, switching valve, and sample injector. The antigens were captured by capture-antibody decorated single-walled carbon nanotubes (SWCNT) fabricated at the bottom of the wells. Then, RuBPY-silica-secondary antibody (Ab2) label was injected to bind to antigen on the array, followed by injection of sacrificial reductant tripropylamine (TPrA) to produce ECL. Potential applied versus Ag/AgCl oxidized TPrA to produce ECL by redox cycling the RuBPY species on the particles, which was measured by a CCD camera. The microfluidic ECL array provided sensitivity at clinically relevant levels of PSA from 100 fg/mL to 10 ng/mL and IL-6 from 10 fg/mL to 1 ng/mL. The LODs were found to be 100 fg/mL (9 zeptomole) for PSA and 10 fg/mL (1 zeptomole) for IL-6. Assay of synthetic human serum samples in microfluidic array was compared with single protein ELISAs, and *t* tests at 95% confidence level confirmed no significant difference between the two methods. Additionally, Li *et al.*³⁴ demonstrated

battery-triggered ECL paper-based immunodevice for multiplexed immunoassay. They used dual-signal amplification strategy by using GO-chitosan/gold nanoparticles (GCA) immunosensing platform and [4,4-(2,5-dimethoxy-1,4-phenylene)bis(ethyne-2,1-diyl) dibenzoic acid] (P-acid) functionalized nanoporous silver (P-acid/NPS) signal amplification label. Corresponding capture antibodies were immobilized onto paper working zones on the back of screen-printed carbon working electrodes. PSA and CEA were detected in the linear ranges of 0.003–20 ng/mL and 0.001–10 ng/mL with the LODs down to 1.0 pg/mL and 0.8 pg/mL, respectively.

Different nanomaterials such as AuNPs and graphene have been employed for microfluidic ECL biomarker detection. Wu *et al.*³⁰ developed a paper-based microfluidic electrochemiluminescence origami cyto-device (μ -PECLOC) with aptamer-modified Au electrodes. Wax-fabricated paper was used for screen-printing of the electrode array. Paper was modified through growth of the layer of Au nanoparticles on the surfaces of cellulose fibers to form 3D macroporous Au-paper cell electrode (PCE) array for the immobilization of aptamers. Owing to the effective disproportionation of hydrogen peroxide and specific recognition of mannose on cell surface, concanavalin-A conjugated porous AuPd alloy nanoparticles were introduced into this μ -PECLOC as the catalytically promoted nanolabels for the peroxydisulfate ECL system. The ECL intensity was found to be logarithmically related to the concentration of MCF-7 cells in the range of 450– 1.0×10^7 cells/mL with the LOD of 250 cells/mL. To further improve the detection performance, nanomaterials with good sensing properties have been incorporated into the microfluidic ECL device. Wang *et al.*³⁵ developed a paper-based 3D microfluidic ECL immunosensor for POC detection of CA-125. To construct a sensitivity-enhanced sandwich-type ECL immunosensor in the microfluidic device, AuNPs were employed as both the pathway of electron transfer and the probe to label the signal antibody. AuNPs can overcome the poor sensitivity, poor stability, and safety problems associated with the use of radioisotopic, fluorescent, and enzyme label.¹⁴⁹ The device had the LOD of 0.0074 U/mL for CA-125. Xu *et al.*¹⁵⁰ established a paper-based solid-state ECL sensor using poly (sodium 4-styrenesulfonate) functionalized graphene/naion composite film for discrimination of single-nucleotide mismatch in human urine matrix. Li *et al.*¹⁵¹ developed a microfluidic paper-based ECL sensor for DNA detection using a graphene-modified Au-paper working electrode and calcium carbonate/carboxymethyl chitosan hybrid microspheres on luminescent silver nanoparticles (AgNPs) composites. The paper-based DNA sensor could detect target DNA in the range of 4.0×10^{-17} – 5.0×10^{-11} M, with the LOD of 8.5×10^{-18} M.

3.6 Other detection methods

Several other detection mechanisms have been utilized on the microfluidic devices. Koh *et al.*¹⁵² developed bead affinity chromatography (BAC) in a temperature controlled PDMS microsystem for detection of biomarkers and preparation of samples for matrix assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) analysis. RNA aptamer-immobilized microbeads capture cancer biomarkers in BAC, which can be denatured and released by controlling the temperature. CEA was concentrated and purified from human serum in the microsystem and detected by MALDI-TOF MS. Mousavi *et al.*¹⁵³ used capped Gold Nanoslit Surface plasmon resonance (SPR) on a PMMA microfluidic chip

for detection of urinary micro-RNA biomarker. They used magnetic nanoparticles for the isolation of target molecule and enhancement of signal in conjunction with SPR on capped gold nanoslit. miRNA-16-5p, a specific and noninvasive biomarker for acute kidney injury (AKI) was detected with a LOD of 17 fM. Zhou *et al.*³⁷ described localized surface plasmon resonance (LSPR) on a glass/poly(olygo (ethylene glycol) methacrylate) (POEGMA) microfluidic device. The fluorescence dyes conjugated to the analyte was excited by plasmonic field to increase the sensitivity. The chip was inserted into a POC system, which had micropumps to control the microfluidic flow, a light source for fluorescence excitation, a camera system for fluorescence detection, and software to automate the POC system and to analyze the result. The LOD for PSA was found to be 100 pg/mL. Tian *et al.*¹⁵⁴ developed a different LSPR-based microfluidic device using antibodies-functionalized gold nanorods on common laboratory filter paper to produce bioplasmonic nanostructure for sensitive detection of bioanalytes in physiological fluids. Zhang *et al.*⁴⁸ developed a PDMS microfluidic device for automatic detection of CEA in exhaled breath condensate (EBC) using long wave surface acoustic wave (SAW) immunosensor. Sandwich immunoassay using antibody labeled with AuNPs and subsequently mass enhancement using gold staining solutions showed good sensitivity with the LOD of 1.25 ng/mL. Due to multiple advantages of bioplasmonic paper such as high specific surface area, mechanical flexibility, compatibility with conventional printing approaches, it was used for rapid and label-free detection of proteins aquaporin-1 (AQP1), a biomarker for early detection of renal cancer carcinoma (RCC), with the LOD of about 24 pg/mL in artificial urine.

4 Conclusions and future perspective

A number of microfluidic platforms including different polymers, paper-based, and hybrid microdevices have been developed for rapid detection of biomarkers of infectious diseases, cancer and other diseases (Table 1). Microfluidic platforms offer many advantages over conventional diagnosis methods, such as low cost, ease of use, high portability or disposability. With the progress in fabrication technology, it is now possible to tailor a fabrication material ranging from polymers to paper and method to match the cost and application of the device. It has been demonstrated that these microfluidic devices have emerged as promising diagnostic platforms to improve human health in low resource settings.

Despite the exciting progress in the field, there are still many hurdles for the application of microfluidic biochips as routine diagnostic devices, especially for the field diagnosis and POC diagnosis in low-resource settings. For example, many microfluidic devices still use complex detection methods and require expensive external equipment, which limits the use of these devices as POC detection in low-resource settings. Although colorimetric detection is highly simple and suitable for low-resource settings, the sensitivity and quantitation are often compromised. Electrochemical detection is highly sensitive and quantitative, but smaller and inexpensive electrochemical analyzers are expected to take advantage of electrochemical detection for the field diagnosis. Optical detection remains an attractive technique for microfluidic analysis of pathogens and proteins, although integrating sensitive optical detectors in inexpensive microfluidics-based devices remains a bottleneck to develop POC devices. An increasing number of new Apps and add-ons enabled powerful

smartphones to have more and more functions for monitoring personal health status.¹⁵⁵ There have been reports of full laboratory-quality immunoassay that can be run on a smartphone accessory.¹⁵⁶ Therefore, we believe that the combination of smartphone technologies with microfluidic devices could cause great impacts on health care (i.e. mHealth) and disease monitoring in the near future to make certain laboratory-based diagnostics accessible to people with smartphone access.

The future trend in microfluidic devices also includes new methods for sample collection and preparation, reagent storage and fully integrated lab-on-a-chip. Sample preparation on chip is often not considered and there are only a small number of devices that offer total analysis on chip.^{57, 157, 158} Microfluidic biochips that can directly test crude real-world samples (e.g. blood, urine, and saliva) may be the alternative to sample preparation on a chip. Similarly, validation of the on-chip detection approaches against real samples is a requirement for successful adoption of these systems by the clinical personnel. Although, there are a vast number of reported microfluidic devices for detection of different diseases, commercialization of these devices and their use outside the research laboratories remain a major challenge. It may be because current clinical diagnostic approaches are well developed and accepted over a long period of time. Hence, the microfluidic platforms do need to solve those challenging real-world issues, and demonstrate robustness and convincing advantages of microfluidic biochips over conventional methods to clinical personnel before they become widely used by clinical personnel. More exciting work is expected from the close collaboration and exchange between the microfluidic lab-on-a-chip community, biology and the clinical communities.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The Li group would like to acknowledge the financial support of the National Institute of Allergy And Infectious Diseases of the National Institutes of Health (NIH) under Award Number R21AI107415, and the National Institute of General Medical Sciences of the NIH under Award Number SC2GM105584. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Financial supports from the IDR Program at the University of Texas at El Paso (UTEP) and the NIH RCMI Pilot Grant are also gratefully acknowledged. F.X. would like to acknowledge the financial support of the Key (Key grant) Project of Chinese Ministry of Education (313045) and International Science & Technology Cooperation Program of China (2013DFG02930).

References

1. Biomedical F. Clin Pharmacol Ther. 2001; 69:89–95. [PubMed: 11240971]
2. Hung LY, Wu HW, Hsieh K, Lee GB. Microfluid Nanofluidics. 2014; 16:941–963.
3. Adamczyk B, Tharmalingam T, Rudd PM. Biochimica et Biophysica Acta (BBA)-General Subjects. 2012; 1820:1347–1353. [PubMed: 22178561]
4. Baylin SB, Jones PA. Nat Rev Cancer. 2011; 11:726–734. [PubMed: 21941284]
5. Luo X, Davis JJ. Chem Soc Rev. 2013; 42:5944–5962. [PubMed: 23615920]
6. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY. The Lancet. 2013; 380:2095–2128.
7. Nelson, KE.; Williams, CM. Infectious disease epidemiology. Jones & Bartlett Publishers; 2012.

8. Yager P, Domingo GJ, Gerdes J. *Annu Rev Biomed Eng.* 2008; 10:107–144. [PubMed: 18358075]
9. Harris, M.; Reza, J. Global report for research on infectious diseases of poverty. World Health Organization; 2012.
10. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. *International Journal of Cancer.* 2015; 136:E359–E386. [PubMed: 25220842]
11. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. *Int J Cancer.* 2015; 136:E359–E386. [PubMed: 25220842]
12. Wild, D. *The Immunoassay Handbook: Theory and applications of ligand binding, ELISA and related techniques.* Newnes; 2013.
13. Innis, MA.; Gelfand, DH.; Sninsky, JJ.; White, TJ. *PCR protocols: a guide to methods and applications.* Academic press; 2012.
14. Jaye DL, Bray RA, Gebel HM, Harris WA, Waller EK. *The Journal of Immunology.* 2012; 188:4715–4719. [PubMed: 22556132]
15. Urdea M, Penny LA, Olmsted SS, Giovanni MY, Kaspar P, Shepherd A, Wilson P, Dahl CA, Buchsbaum S, Moeller G. *Nature.* 2006; 444:73–79. [PubMed: 17159896]
16. Li X, Li PC. *Expert Rev Clin Pharmacol.* 2010; 3:267–280. [PubMed: 22111609]
17. Arora A, Simone G, Salieb-Beugelaar GB, Kim JT, Manz A. *Anal Chem.* 2010; 82:4830–4847. [PubMed: 20462185]
18. Kovarik ML, Gach PC, Orloff DM, Wang Y, Balowski J, Farrag L, Allbritton NL. *Anal Chem.* 2011; 84:516–540. [PubMed: 21967743]
19. Hu J, Wang S, Wang L, Li F, Pingguan-Murphy B, Lu TJ, Xu F. *Biosens Bioelectron.* 2014; 54:585–597. [PubMed: 24333570]
20. Wang S, Xu F, Demirci U. *Biotech Adv.* 2010; 28:770–781.
21. Shen F, Li X, Li PCH. *Biomicrofluidics.* 2014; 8:014109. [PubMed: 24753729]
22. Li, XJ.; Zhou, Y. *Microfluidic devices for biomedical applications.* Elsevier; 2013.
23. Liang J, Wang Y, Liu B. *RSC Adv.* 2012; 2:3878–3884.
24. Qi H, Huang G, Han YL, Lin W, Li X, Wang S, Lu TJ, Xu F. *Crit Rev Biotechnol.* Jul 15.2014 :1–12. [PubMed: 23190337]
25. Li X, Li PC. *Can J Pure & Appl Sci.* 2014; 8:2663–2669.
26. Li X, Chen Y, Li PC. *Lab Chip.* 2011; 11:1378–1384. [PubMed: 21327253]
27. Li X, Ling V, Li PC. *Anal Chem.* 2008; 80:4095–4102. [PubMed: 18447319]
28. Chen H, Li X, Wang L, Li PC. *Talanta.* 2010; 81:1203–1208. [PubMed: 20441885]
29. Li X, Valadez AV, Zuo P, Nie Z. *Bioanalysis.* 2012; 4:1509–1525. [PubMed: 22793034]
30. Wu L, Ma C, Ge L, Kong Q, Yan M, Ge S, Yu J. *Biosens Bioelectron.* 2015; 63:450–457. [PubMed: 25128625]
31. Wu Y, Xue P, Hui KM, Kang Y. *Biosens Bioelectron.* 2014; 52:180–187. [PubMed: 24055931]
32. Wang S, Ge L, Song X, Yu J, Ge S, Huang J, Zeng F. *Biosens Bioelectron.* 2012; 31:212–218. [PubMed: 22051546]
33. Wang P, Ge L, Yan M, Song X, Ge S, Yu J. *Biosens Bioelectron.* 2012; 32:238–243. [PubMed: 2226410]
34. Li W, Li M, Ge S, Yan M, Huang J, Yu J. *Anal chem acta.* 2013; 767:66–74.
35. Wang S, Ge L, Yan M, Yu J, Song X, Ge S, Huang J. *Sensors Actuat B-Chem.* 2013; 176:1–8.
36. Sardesai NP, Kadimisetty K, Faria R, Rusling JF. *Anal Bioanal Chem.* 2013; 405:3831–3838. [PubMed: 23307128]
37. Zhou XD, Wong TI, Song HY, Wu L, Wang Y, Bai P, Kim DH, Ng SH, Tse MS, Knoll W. *Plasmonics.* 2014; 9:835–844.
38. Jokerst JC, Adkins JA, Bisha B, Mentele MM, Goodridge LD, Henry CS. *Anal Chem.* 2012; 84:2900–2907. [PubMed: 22320200]
39. Yu L, Li CM, Liu Y, Gao J, Wang W, Gan Y. *Lab Chip.* 2009; 9:1243–1247. [PubMed: 19370243]
40. Dou M, Dominguez DC, Li X, Sanchez J, Scott G. *Analytical Chemistry.* 2014; 86:7978–7986. [PubMed: 25019330]

41. Dou M, Dominguez DC, Li X, Sanchez J, Scott G. *Anal Chem*. 2014; 86:7978–7986. [PubMed: 25019330]
42. Lee YF, Lien KY, Lei HY, Lee GB. *Biosens Bioelectron*. 2009; 25:745–752. [PubMed: 19744849]
43. Horak J, Dincer C, Qelibari E, Bakirci H, Urban G. *Sensors Actuat B-Phys*. 2014; 209:478–485.
44. Li XJ, Li PCH. *Anal Chem*. 2005; 77:4315–4322. [PubMed: 16013841]
45. Medina-Sánchez M, Miserere S, Morales-Narváez E, Merkoçi A. *Biosens Bioelectron*. 2014; 54:279–284. [PubMed: 24287417]
46. Li XJ, Xue X, Li PCH. *Integr Biol*. 2009; 1:90–98.
47. Li XJ, Huang J, Tibbits GF, Li PCH. *Electrophoresis*. 2007; 28:4723–4733. [PubMed: 18072214]
48. Zhang X, Zou Y, An C, Ying K, Chen X, Wang P. *Sensors Actuat B-Phys*. 2014; 205:94–101.
49. Chikkaveeraiah BV, Mani V, Patel V, Gutkind JS, Rusling JF. *Biosens Bioelectron*. 2011; 26:4477–4483. [PubMed: 21632234]
50. Mohammed M, Desmulliez M. *Biosens Bioelectron*. 2014; 61:478–484. [PubMed: 24934750]
51. Matos Pires NM, Dong T. *Sensors*. 2013; 13:15898–15911. [PubMed: 24287522]
52. Jena RK, Yue C, Lam Y. *Microsystem technologies*. 2012; 18:159–166.
53. Yu H, Tor S, Loh N. *Journal of Micromechanics and Microengineering*. 2014; 24:115020.
54. Ornatka M, Sharpe E, Andreescu D, Andreescu S. *Anal Chem*. 2011; 83:4273–4280. [PubMed: 21524141]
55. Su M, Ge L, Ge S, Li N, Yu J, Yan M, Huang J. *Anal Chim Acta*. 2014; 847:1–9. [PubMed: 25261894]
56. Hu J, Wang L, Li F, Han YL, Lin M, Lu TJ, Xu F. *Lab Chip*. 2013; 13:4352–4357. [PubMed: 24056409]
57. Liu P, Li X, Greenspoon SA, Scherer JR, Mathies RA. *Lab Chip*. 2011; 11:1041–1048. [PubMed: 21293830]
58. Liu XY, Cheng CM, Martinez AW, Mirica KA, Li XJ, Phillips ST, Mascarenas M, Whitesides GM. *Proc Ieee Micr Elect*. 2011:75–78.
59. Liu XY, O'Brien M, Mwangi M, Li XJ, Whitesides GM. *Proc Ieee Micr Elect*. 2011:133–136.
60. Han YL, Wang W, Hu J, Huang G, Wang S, Lee WG, Lu TJ, Xu F. *Lab Chip*. 2013; 13:4745–4749. [PubMed: 24172608]
61. Wang S, Inci F, Chaunzwa TL, Ramanujam A, Vasudevan A, Subramanian S, Ip ACF, Sridharan B, Gurkan UA, Demirci U. *International journal of nanomedicine*. 2012; 7:2591. [PubMed: 22679370]
62. Ashley JF, Cramer NB, Davis RH, Bowman CN. *Lab Chip*. 2011; 11:2772–2778. [PubMed: 21691663]
63. Devaraju NSGK, Unger MA. *Lab Chip*. 2011; 11:1962–1967. [PubMed: 21503367]
64. Xia Y, Whitesides GM. *Annu Rev Mater Sci*. 1998; 28:153–184.
65. Nie Z, Nijhuis CA, Gong J, Chen X, Kumachev A, Martinez AW, Narovlyansky M, Whitesides GM. *Lab Chip*. 2010; 10:477–483. [PubMed: 20126688]
66. Liu X, Mwangi M, Li X, O'Brien M, Whitesides GM. *Lab Chip*. 2011; 11:2189–2196. [PubMed: 21566813]
67. Becker H, Gärtner C. *Anal Bioanal Chem*. 2008; 390:89–111. [PubMed: 17989961]
68. Yetisen AK, Akram MS, Lowe CR. *Lab Chip*. 2013; 13:2210–2251. [PubMed: 23652632]
69. Sollier E, Murray C, Maoddi P, Di Carlo D. *Lab Chip*. 2011; 11:3752–3765. [PubMed: 21979377]
70. Kung YC, Huang KW, Fan YJ, Chiou PY. *Lab Chip*. 2015; 15:1861–1868. [PubMed: 25710255]
71. Qin D, Xia Y, Whitesides GM. *Nature protocols*. 2010; 5:491–502. [PubMed: 20203666]
72. Comina G, Suska A, Filippini D. *Lab Chip*. 2014; 14:424–430. [PubMed: 24281262]
73. Rasooly, A.; Bruck, HA.; Kostov, Y. *Microfluidic Diagnostics*. Springer; 2013. p. 451–471.
74. Cassano CL, Simon AJ, Liu W, Fredrickson C, Fan ZH. *Lab Chip*. 2015; 15:62–66. [PubMed: 25329244]
75. Becker H, Heim U. *Sensors Actuat A-Phys*. 2000; 83:130–135.

76. Mathiesen, D.; Dupaix, R. Challenges in Mechanics of Time-Dependent Materials. Vol. 2. Springer; 2015. p. 73-80.
77. Suriano R, Kuznetsov A, Eaton SM, Kiyan R, Cerullo G, Osellame R, Chichkov BN, Levi M, Turri S. Applied Surface Science. 2011; 257:6243–6250.
78. Zema L, Loreti G, Melocchi A, Maroni A, Gazzaniga A. J Controlled Release. 2012; 159:324–331.
79. Roy E, Galas JC, Veres T. Lab Chip. 2011; 11:3193–3196. [PubMed: 21796278]
80. Miserere S, Mottet G, Taniga V, Descroix S, Viovy JL, Malaquin L. Lab Chip. 2012; 12:1849–1856. [PubMed: 22487893]
81. Rahmanian O, DeVoe DL. Lab Chip. 2013; 13:1102–1108. [PubMed: 23344819]
82. Yang CS, Lin CH, Zaytsev A, Teng KC, Her TH, Pan CL. Applied Physics Letters. 2015; 106:051902.
83. Lu Y, Shi W, Jiang L, Qin J, Lin B. Electrophoresis. 2009; 30:1497–1500. [PubMed: 19340829]
84. Li X, Tian J, Garnier G, Shen W. Colloids Surf, B. 2010; 76:564–570.
85. Martinez AW, Phillips ST, Butte MJ, Whitesides GM. Angew Chem Int Ed. 2007; 46:1318–1320.
86. Martinez AW, Phillips ST, Wiley BJ, Gupta M, Whitesides GM. Lab Chip. 2008; 8:2146–2150. [PubMed: 19023478]
87. Dungchai W, Chailapakul O, Henry CS. Analyst. 2011; 136:77–82. [PubMed: 20871884]
88. Huang KF, Lee YC. Journal of Vacuum Science & Technology B. 2013; 31:031604.
89. Chan HN, Chen Y, Shu Y, Chen Y, Tian Q, Wu H. Microfluid Nanofluidics. 2015; 1–10.
90. He Q, Ma C, Hu X, Chen H. Anal Chem. 2013; 85:1327–1331. [PubMed: 23244032]
91. Olkkonen J, Lehtinen K, Erho T. Anal Chem. 2010; 82:10246–10250. [PubMed: 21090744]
92. Songjaroen T, Dungchai W, Chailapakul O, Laiwattanapaisa W. Talanta. 2011; 85:2587–2593. [PubMed: 21962687]
93. Carrilho E, Martinez AW, Whitesides GM. Anal Chem. 2009; 81:7091–7095. [PubMed: 20337388]
94. Sameenoi Y, Nongkai PN, Nouanthavong S, Henry CS, Nacapricha D. Analyst. 2014; 139:6580–6588. [PubMed: 25360590]
95. Zuo P, Li X, Dominguez DC, Ye BC. Lab Chip. 2013; 13:3921–3928. [PubMed: 23929394]
96. Fu E, Lutz B, Kauffman P, Yager P. Lab Chip. 2010; 10:918–920. [PubMed: 20300678]
97. Thuo MM, Martinez RV, Lan WJ, Liu X, Barber J, Atkinson MB, Bandarage D, Bloch JF, Whitesides GM. Chem Mat. 2014; 26:4230–4237.
98. Vilela D, González MC, Escarpa A. Anal Chim Acta. 2012; 751:24–43. [PubMed: 23084049]
99. Qu W, Liu Y, Liu D, Wang Z, Jiang X. Angew Chem. 2011; 123:3504–3507.
100. Wu L, Qu X. Chem Soc Rev. 2015; 44:2963–2997. [PubMed: 25739971]
101. Li X, Ballerini DR, Shen W. Biomicrofluidics. 2012; 6:011301.
102. Gao Z, Xu M, Lu M, Chen G, Tang D. Biosens Bioelectron. 2015; 70:194–201. [PubMed: 25814409]
103. Fang WF, Chen WJ, Yang JT. Sensors Actuat B-Phys. 2014; 192:77–82.
104. Yu L, Liu Y, Gan Y, Li CM. Biosens Bioelectron. 2009; 24:2997–3002. [PubMed: 19346122]
105. Park J, Sunkara V, Kim TH, Hwang H, Cho YK. Anal Chem. 2012; 84:2133–2140. [PubMed: 22277086]
106. Fang X, Liu Y, Kong J, Jiang X. Anal Chem. 2010; 82:3002–3006. [PubMed: 20218572]
107. Wang W, Wu WY, Wang W, Zhu JJ. J Chromatogr A. 2010; 1217:3896–3899. [PubMed: 20444459]
108. Ahmed HA, Azzazy HM. Biosens Bioelectron. 2013; 49:478–484. [PubMed: 23811482]
109. Dungchai W, Chailapakul O, Henry CS. Anal Chim Acta. 2010; 674:227–233. [PubMed: 20678634]
110. Lei KF, Butt YK. Microfluid Nanofluidics. 2010; 8:131–137.
111. Liang L, Ge S, Li L, Liu F, Yu J. Anal Chim Acta. 2015; 862:70–76. [PubMed: 25682430]
112. Kumar A, Hens A, Arun RK, Mahato K, Chatterjee M, Layek K, Chanda N. Analyst. 2015; 140:1817–1821. [PubMed: 25655365]

113. Baeissa A, Dave N, Smith BD, Liu J. ACS applied materials & interfaces. 2010; 2:3594–3600. [PubMed: 21077647]
114. Wang CH, Chang CJ, Wu JJ, Lee GB. Nanomedicine: Nanotechnology, Biology and Medicine. 2014; 10:809–818.
115. Diercks AH, Ozinsky A, Hansen CL, Spotts JM, Rodriguez DJ, Aderem A. Anal Biochem. 2009; 386:30–35. [PubMed: 19133224]
116. Castro-López V, Elizalde J, Pacek M, Hijona E, Bujanda L. Biosens Bioelectron. 2014; 54:499–505. [PubMed: 24316452]
117. Wang X, Theodore MJ, Mair R, Trujillo-Lopez E, du Plessis M, Wolter N, Baughman AL, Hatcher C, Vuong J, Lott L. Journal of clinical microbiology. 2012; 50:702–708. [PubMed: 22170919]
118. Jing W, Zhao W, Liu S, Li L, Tsai CT, Fan X, Wu W, Li J, Yang X, Sui G. Anal Chem. 2013; 85:5255–5262. [PubMed: 23590462]
119. Joensson HN, Samuels ML, Brouzes ER, Medkova M, Uhlén M, Link DR, Andersson-Svahn H. Angew Chem Int Ed. 2009; 48:2518–2521.
120. Lin YH, Wang CC, Lei KF. Biomedical microdevices. 2014; 16:199–207. [PubMed: 24141738]
121. Riahi R, Gogoi P, Sepehri S, Zhou Y, Handique K, Godsey J, Wang Y. International journal of oncology. 2014; 44:1870–1878. [PubMed: 24676558]
122. Hu M, Yan J, He Y, Lu H, Weng L, Song S, Fan C, Wang L. Acs Nano. 2009; 4:488–494. [PubMed: 20041634]
123. Zhang H, Liu L, Fu X, Zhu Z. Biosens Bioelectron. 2013; 42:23–30. [PubMed: 23202325]
124. Yu X, Xia HS, Sun ZD, Lin Y, Wang K, Yu J, Tang H, Pang DW, Zhang ZL. Biosens Bioelectron. 2013; 41:129–136. [PubMed: 22940194]
125. Hoffman JM, Stayton PS, Hoffman AS, Lai JJ. Bioconjugate chemistry. 2014; 26(1):29–38. [PubMed: 25405605]
126. Maxwell EJ, Mazzeo AD, Whitesides GM. MRS bulletin. 2013; 38:309–314.
127. Ahmed MU, Hossain MM, Safavieh M, Wong YL, Rahman IA, Zourob M, Tamiya E. Crit Rev Biotechnol. 2015:1–11. [PubMed: 25578718]
128. Su W, Gao X, Jiang L, Qin J. J Chromatogr A. 2014; 1377:13–26. [PubMed: 25544727]
129. Chikkaveeraiah BV, Bhird AA, Morgan NY, Eden HS, Chen X. ACS nano. 2012; 6:6546–6561. [PubMed: 22835068]
130. Li X, Nie Z, Cheng C, Goodale A, Whitesides G. Proc Micro Total Analysis Systems. 2010; 14:1487–1489.
131. Sun G, Ding Y-n, Ma C, Zhang Y, Ge S, Yu J, Song X. Electrochimica Acta. 2014; 147:650–656.
132. Bai Y, Koh CG, Boreman M, Juang YJ, Tang IC, Lee LJ, Yang ST. Langmuir. 2006; 22:9458–9467. [PubMed: 17042569]
133. Liu Y, Wang H, Huang J, Yang J, Liu B, Yang P. Anal Chim Acta. 2009; 650:77–82. [PubMed: 19720177]
134. Zhou F, Lu M, Wang W, Bian ZP, Zhang JR, Zhu JJ. Clinical chemistry. 2010; 56:1701–1707. [PubMed: 20852134]
135. Liang W, Li Y, Zhang B, Zhang Z, Chen A, Qi D, Yi W, Hu C. Biosens Bioelectron. 2012; 31:480–485. [PubMed: 22169814]
136. Zhao C, Thuo MM, Liu X. Science and Technology of Advanced Materials. 2013; 14:054402.
137. Ben-Yoav H, Dykstra PH, Bentley WE, Ghodssi R. Biosens Bioelectron. 2015; 64:579–585. [PubMed: 25310492]
138. Iranifam M. TrAC Trends in Analytical Chemistry. 2014; 59:156–183.
139. Pires NMM, Dong T, Hanke U, Hoivik N. Sensors. 2014; 14:15458–15479. [PubMed: 25196161]
140. Ge L, Wang S, Song X, Ge S, Yu J. Lab Chip. 2012; 12:3150–3158. [PubMed: 22763468]
141. Pires NMM, Dong T, Hanke U, Hoivik N. Journal of biomedical optics. 2013; 18:097001–097001. [PubMed: 24002194]
142. Liu W, Wei H, Lin Z, Mao S, Lin J-M. Biosens Bioelectron. 2011; 28:438–442. [PubMed: 21856143]

143. Yang M, Kostov Y, Bruck HA, Rasooly A. International journal of food microbiology. 2009; 133:265–271. [PubMed: 19540011]
144. Zhao X, Dong T. Sensors. 2013; 13:14570–14582. [PubMed: 24169541]
145. Hu L, Xu G. Chem Soc Rev. 2010; 39:3275–3304. [PubMed: 20593100]
146. Tomazelli Coltro WK, Cheng CM, Carrilho E, Jesus DP. Electrophoresis. 2014; 35:2309–2324. [PubMed: 24668896]
147. Ge L, Yan J, Song X, Yan M, Ge S, Yu J. Biomaterials. 2012; 33:1024–1031. [PubMed: 22074665]
148. Yang H, Kong Q, Wang S, Xu J, Bian Z, Zheng X, Ma C, Ge S, Yu J. Biosens Bioelectron. 2014; 61:21–27. [PubMed: 24841090]
149. Qi Y, Li B. Chemistry-A European Journal. 2011; 17:1642–1648.
150. Xu Y, Lou B, Lv Z, Zhou Z, Zhang L, Wang E. Anal Chim Acta. 2013; 763:20–27. [PubMed: 23340282]
151. Li M, Wang Y, Zhang Y, Yu J, Ge S, Yan M. Biosens Bioelectron. 2014; 59:307–313. [PubMed: 24747206]
152. Koh Y, Lee BR, Yoon HJ, Jang YH, Lee YS, Kim YK, Kim BG. Anal Bioanal Chem. 2012; 404:2267–2275. [PubMed: 22986986]
153. Mousavi MZ, Chen H-Y, Lee K-L, Lin H, Chen H-H, Lin Y-F, Wong CS, Li H-F, Wei P-K, Cheng J-Y. Analyst. 2015; 140:4097–4104. [PubMed: 25891475]
154. Tian L, Morrissey JJ, Kattumenu R, Gandra N, Kharasch ED, Singamaneni S. Anal Chem. 2012; 84:9928–9934. [PubMed: 23098272]
155. Xu X, Akay A, Wei H, Wang S, Pingguan-Murphy B, Erlandsson B-E, Li X, Lee W, Hu J, Wang L. Proceedings of the IEEE. 2015; 103:236–247.
156. Laksanasopin T, Guo TW, Nayak S, Sridhara AA, Xie S, Olowookere OO, Cadinu P, Meng F, Chee NH, Kim J. Sci Transl Med. 2015; 7:273re271–273re271.
157. Lee BS, Lee YU, Kim HS, Kim TH, Park J, Lee JG, Kim J, Kim H, Lee WG, Cho YK. Lab Chip. 2011; 11:70–78. [PubMed: 21042620]
158. Nguyen J, Wei Y, Zheng Y, Wang C, Sun Y. Lab Chip. 2015; 15:1533–1544. [PubMed: 25631744]

Figure 1.

Fabrication schematic of 3D high aspect ratio PDMS microfluidic networks using a plastic plate embedded hybrid stamp. Reproduced with permission from Royal Society of Chemistry.⁷⁰

Figure 2.

Paper-based and its hybrid microfluidic platforms. (A) FLASH fabrication for paper-based microfluidic devices. (1) Schematic of the method. (2)–(5) FLASH fabrication procedures. Reproduced with permission from Royal Society of Chemistry.⁸⁶ (B) A PDMS/paper hybrid chip for instrument-free diagnosis of infectious diseases using a UV light pen. Reproduced with permission from American Chemical Society.⁴¹

Figure 3. Biomarker detection using integrated nano-sensors on the chip. (A) Schematic of the working principle of the colorimetric assays for detection of glucose with cerium oxide nanoparticles using a paper-based microfluidic device. Reproduced with permission from American Chemical Society.⁵⁴ (B) Schematic of a PDMS/paper hybrid chip for multiplexed one-step pathogen detection using graphene oxide (GO) nanosensors. (1) The hybrid microfluidic biochip layout. (2) and (3) One step turn-on detection based on interaction among GO, aptamers and pathogens. (4) Cross-reaction investigation of *Staphylococcus aureus* and *Salmonella enterica* with their corresponding and non-corresponding aptamers. Reproduced with permission Royal Society of Chemistry.⁹⁵

Figure 4.

A paper-based microfluidic platform with electrochemical detection for multiplexed cancer biomarker detection. (A) Device fabrication procedures. (B) Schematic representation of the electrochemical immunoassay procedures using CEA as an example. Reproduced with permission from Elsevier.³¹

Figure 5.

Biomarker detection on microfluidic platforms with chemiluminescence and electrochemiluminescence detection. (A) Schematic representation of rare cell capture and detection using aptamers and chemiluminescence. Reproduced with permission from Elsevier.¹⁴² (B) Microfluidic electrochemiluminescence array for cancer biomarker detection. 1) syringe pump; 2) injector valve; 3) switch valve; 4) tubing for inlet; 5) outlet; 6) PMMA plate; 7) Pt counter wire; 8) Ag/AgCl reference wire; 9) PDMS channels; 10) pyrolytic graphite chip; 11) Immunoassay complex on RuBYP-silica nanoparticles. Reproduced with permission from Springer.³⁶

Table 1

Summary of biomarker detection using microfluidic platforms

	Specific disease	Biomarkers	LOD	Detection Method	Microfluidic platform	Ref
Cancer	Colorectal carcinoma	CEA	250 fM	Fluorescent	PDMS	122
		CEA	3.5 ng/mL	Fluorescent	PDMS	124
		CEA	0.01 ng/mL	Electrochemical	Paper	31
		CEA	0.01 ng/mL	Electrochemical	Paper	33
		CEA	0.05 ng/mL	Chemiluminescence	Paper	32
		CEA	0.02 ng/mL	Chemiluminescence	Paper	140
		CEA	0.5 ng/mL	ECL	Paper	147
		CEA	0.8 pg/mL	ECL	Paper	34
		CEA	1.25 ng/mL	SAW	PDMS	48
		CEA	0.3 pg/mL	Electrochemical	Paper	131
		CEA	1.7 pg/mL	Colorimetric	Paper	111
		AFP	250 fM	Fluorescent	PDMS	122
		AFP	0.01 ng/mL	Electrochemical	Paper	31
		AFP	1 pg/mL	Electrochemical	PMMA	133
	AFP	0.06 ng/mL	Chemiluminescence	Paper	32	
	AFP	1 ng/mL	Chemiluminescence	Paper	140	
	AFP	0.15 ng/mL	ECL	Paper	147	
	AFP	3.9 ng/mL	Fluorescent	PDMS	124	
	AFP	0.2 fg/chip	Fluorescent	PDMS	123	
	AFP	1.7 pg/mL	Colorimetric	Paper	111	
Ovarian cancer	CA-125	0.05 ng/mL	Electrochemical	Paper	31	
	CA-125	0.2 mU/mL	Electrochemical	Paper	33	
	CA-125	0.33 ng/mL	Chemiluminescence	Paper	32	
	CA-125	0.6 U/mL	ECL	Paper	147	
	CA-125	0.0074 U/mL	ECL	Paper	35	

Specific disease	Biomarkers	LOD	Detection Method	Microfluidic platform	Ref
Prostate cancer	PSA	0.23 pg/mL	Electrochemical	PDMS	49
	PSA	100 fg/mL	ECL	PMMA/PDMS	36
	PSA	1 pg/mL	ECL	Paper	34
	PSA	100 pg/mL	LSPR	POEGMA/glass	37
	PSA	3.2 ng/mL	Colorimetric	PMMA	108
	PSA	0.5 pM	Fluorescent	PNIPAAm	125
	PSA	100 pg/mL	ECL	POEGMA/glass	37
	IL-6	0.30 pg/mL	Electrochemical	PDMS	49
	IL-6	10 fg/mL	ECL	PMMA/PDMS	36
	CA-199	0.17 U/mL	ECL	Paper	147
Pancreatic cancer	CA-199	0.0055 U/mL	ECL	Paper	148
	CA-199	0.06 U/mL	Chemiluminescence	Paper	140
	CA153	0.05 ng/mL	Electrochemical	Paper	31
Breast cancer	CA153	0.4 U/mL	Chemiluminescence	Paper	140
	HL-60	350 cells/mL	Electrochemical	Paper	55
Human acute leukemia	CCL-119	30 cells/3 μ L	Chemiluminescence	PDMS	142
	AQP1	24 pg/mL	LSPR	Paper	154
Renal cancer carcinoma	APOA1	9.16 ng/mL	Fluorescent	PDMS	120
Bladder cancer	TNF	3.1 pg/mL	Fluorescent	Cyclo-olefin	116
	TNF	1000 copies/4.7 mL	Fluorescent	PDMS	115
Infectious disease	Hepatitis B	100 pg/mL	Colorimetric	PDMS	39
	Pseudorabies virus	10 fg/ μ L	Colorimetric	PDMS	106
	Dengue virus	21 pg/mL	Fluorescent	PDMS	42
	Meningitis	3 copies/LAMP zone	Fluorescent	PDMS/paper hybrid	41
	Food-borne disease	0.01 ng/mL	Chemiluminescence	Polycarbonate	143
	Food-borne pathogens	61 cfu/mL	Fluorescent	PDMS/paper hybrid	95
		800 cfu/mL	Fluorescent	PDMS/paper hybrid	95
	<i>E. coli</i>	5×10^5 cells/mL	Chemiluminescence	PMMA	51

	Specific disease	Biomarkers	LOD	Detection Method	Microfluidic platform	Ref
		<i>C. jejuni</i>	1×10^5 cells/mL	Chemiluminescence	PMMA	51
		IgG	3.9 fM	Electrochemical	Paper	130
		IgG	10 pg/mL	Colorimetric	PDMS	104
Other diseases	Diabetics	Glucose	0.5 mM	Colorimetric	Paper	54
		Glucose	0.35mM	Electrochemical	Paper	136
	Thyroid dysfunction	Human thyroid stimulating hormone	68 pg/mL	Chemiluminescence	PDMS/glass	141
	Cardiovascular disease	cTnI	5 amol/30 μ L	Electrochemical	PDMS	134
		cTnI	25 pg/mL	Electrochemical	Vacrel® 8100 photoresist	43
		cTnI	0.51 ng/mL	Colorimetric	PMMA	105
		cTnI	24 pg/mL	Fluorescent	PMMA	50
		CRP	307 amol/30 μ L	Electrochemical	PDMS	134
	Alzheimer's disease	CRP	0.30 ng/mL	Colorimetric	PMMA	105
		NT-proBNP	0.03 ng/mL	Electrochemical		135
		NT-proBNP	0.24 ng/mL	Colorimetric	PMMA	105
	Bronchial asthma	ApoE	12.5 ng/mL	Electrochemical	PDMS	45
		IL-5	100 pg/mL	Colorimetric	PDMS	39
	Neuromyelitis optica	IgG	100 pg/mL	Colorimetric	PDMS	39
		Uric acid	0.52 mM	Electrochemical	Paper	136
		Uric acid	8.1 ppm	Colorimetric	Paper	112
		Lactate	1.76 mM	Electrochemical	Paper	136